Vaxxas, a clinical-stage biotech company, has broadened its global intellectual property portfolio to include 42 patents, reinforcing its exclusive rights to manufacture and sell its proprietary high-density microarray patch (HD-MAP) vaccination technology across the United States, Europe, Asia, and Australia.
Vaxxas has expanded its intellectual property portfolio to include patents covering key aspects of its vaccine delivery platform, including the high-density microarray patch (HD-MAP) technology, applicator devices, vaccine formulations, and methods for formulating, loading, and coating vaccines on the HD-MAP.
In November 2024, Vaxxas was granted a new patent in the U.S. for the design and use of its HD-MAP and applicator technology for skin-based vaccine delivery. This patent strengthens Vaxxas’ position in the vaccine market.
Vaxxas CEO and President, David Hoey, stated, “We are focused on transforming the vaccine market by enhancing vaccine performance and addressing the logistical challenges associated with traditional needle-and-syringe delivery. Our growing patent portfolio ensures we can exclusively use these technologies and manufacture and sell our products safely and in compliance with regulatory standards.”
Vaxxas’ Chief Technology Officer, Dr. Angus Forster, emphasized that the company has strategically built its global IP portfolio. “The comprehensive geographical and technological coverage of our patents distinguishes us as we advance our vaccination platform and expand our product range,” said Dr. Forster. “In the past two years, we’ve filed seven new patents, including for HD-MAP delivery of mRNA vaccines, with potential protection through 2045.”
Vaxxas is scaling up production of the world’s first commercially available vaccine patches at its state-of-the-art facility in Brisbane. COO Scott Fry noted that the company has extensive patenting opportunities, as it develops combination products that integrate vaccines and medical devices. “We file patents not just for the vaccines we deliver, but also for the systems and processes involved in manufacturing HD-MAPs and applicators at scale,” he said.
The company has successfully completed five Phase I clinical trials with over 500 participants, addressing major global health concerns such as COVID-19, flu, and measles. Vaxxas is also conducting its first U.S. IND-enabled Phase I study for a pre-pandemic influenza vaccine, with support from the U.S. Biomedical Advanced Research and Development Authority (BARDA).
About Vaxxas:
Vaxxas is a privately held biotech company focused on enhancing the performance of vaccines through its proprietary HD-MAP technology. With successful clinical trials for COVID-19, influenza, and measles vaccines, Vaxxas is advancing its platform toward commercialization, targeting infectious diseases and oncology. The company was founded in 2011 based on technology developed at the University of Queensland and has received funding from OneVentures, Brandon Capital Partners, and U.S.-based HealthCare Ventures.
About HD-MAP Needle-Free Vaccines:
The Vaxxas HD-MAP consists of thousands of microscopic projections coated with a small dose of vaccine in a dried formulation. When applied to the skin, the patch delivers the vaccine to immune cells just beneath the surface. HD-MAP technology has the potential to overcome challenges of traditional vaccine delivery, offering greater stability at higher temperatures and reducing cold-chain storage needs. Early clinical studies have shown that HD-MAP delivers equal or stronger immune responses than needle injections, with easier administration and potential benefits for future pandemic responses.
